Arkema

ARKEMA FADES AWAY (BUY; +39% UPSIDE)

03/09/24 -" Portfolio rotation has been a key profitability driver and a crucial aspect of Arkema’s (Buy; France) equity narrative. Its 2028 targets appear to be more of the same, and achieving them becomes ..."

PDF page sample
Pages
62
Language
English
Published on
03/09/24
Download
You may also be interested by these reports :
03/11/25
Fuchs’ Q3 2025 results, although muted, came in line with street expectations. Sales were supported by strong performance in Asia and the Americas. ...
03/11/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
01/11/25
Linde released a decent set of results for Q325. Of margins have help up, it is worth mentioning that the topline growth makes it impossible to ...
31/10/25
Wacker delivered mixed Q3 2025 results as weak demand and prices – partly a consequence of Chinese oversupply – weighed on sales. While EBITDA beat ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO